EVOLENT HEALTH ($EVH) posted quarterly earnings results on Thursday, May 8th. The company reported earnings of $0.06 per share, missing estimates of $0.10 by $0.04. The company also reported revenue of $483,650,000, beating estimates of $464,914,110 by $18,735,890.
You can see Quiver Quantitative's $EVH stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
EVOLENT HEALTH Insider Trading Activity
EVOLENT HEALTH insiders have traded $EVH stock on the open market 11 times in the past 6 months. Of those trades, 11 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $EVH stock by insiders over the last 6 months:
- SETH BLACKLEY (Chief Executive Officer) purchased 55,225 shares for an estimated $497,577
- RICHARD M JELINEK has made 2 purchases buying 30,000 shares for an estimated $273,750 and 0 sales.
- BRENDAN B SPRINGSTUBB has made 2 purchases buying 20,000 shares for an estimated $182,800 and 0 sales.
- KIM KECK purchased 10,540 shares for an estimated $99,497
- PETER J GRUA purchased 11,040 shares for an estimated $99,470
- DANIEL JOSEPH MCCARTHY (PRESIDENT) purchased 11,040 shares for an estimated $99,470
- RUSSELL MONROE GLASS purchased 5,400 shares for an estimated $50,058
- DIANE HOLDER purchased 2,735 shares for an estimated $25,517
- CRAIG A. BARBAROSH purchased 2,000 shares for an estimated $17,620
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
EVOLENT HEALTH Hedge Fund Activity
We have seen 129 institutional investors add shares of EVOLENT HEALTH stock to their portfolio, and 151 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CADIAN CAPITAL MANAGEMENT, LP added 5,225,001 shares (+inf%) to their portfolio in Q4 2024, for an estimated $58,781,261
- RA CAPITAL MANAGEMENT, L.P. removed 4,937,665 shares (-58.0%) from their portfolio in Q4 2024, for an estimated $55,548,731
- CAMBER CAPITAL MANAGEMENT LP added 2,600,000 shares (+185.7%) to their portfolio in Q4 2024, for an estimated $29,250,000
- FIRST LIGHT ASSET MANAGEMENT, LLC removed 2,244,641 shares (-97.7%) from their portfolio in Q4 2024, for an estimated $25,252,211
- WELLINGTON MANAGEMENT GROUP LLP removed 2,158,964 shares (-17.1%) from their portfolio in Q4 2024, for an estimated $24,288,345
- LAZARD ASSET MANAGEMENT LLC removed 1,726,255 shares (-72.8%) from their portfolio in Q4 2024, for an estimated $19,420,368
- ORBIMED ADVISORS LLC removed 1,665,115 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $18,732,543
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
EVOLENT HEALTH Analyst Ratings
Wall Street analysts have issued reports on $EVH in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- UBS issued a "Buy" rating on 01/16/2025
- RBC Capital issued a "Outperform" rating on 01/14/2025
- JMP Securities issued a "Outperform" rating on 01/10/2025
- Needham issued a "Buy" rating on 01/10/2025
- Oppenheimer issued a "Outperform" rating on 11/18/2024
To track analyst ratings and price targets for EVOLENT HEALTH, check out Quiver Quantitative's $EVH forecast page.
EVOLENT HEALTH Price Targets
Multiple analysts have issued price targets for $EVH recently. We have seen 5 analysts offer price targets for $EVH in the last 6 months, with a median target of $18.0.
Here are some recent targets:
- Kevin Caliendo from UBS set a target price of $14.0 on 01/16/2025
- Jailendra Singh from Truist Financial set a target price of $20.0 on 01/15/2025
- Sean Dodge from RBC Capital set a target price of $17.0 on 01/14/2025
- Constantine Davides from JMP Securities set a target price of $18.0 on 01/10/2025
- Mohan Naidu from Oppenheimer set a target price of $28.0 on 11/18/2024
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
